Abstract:ID 92916 Poster Board 479 Dopamine receptors (DARs) are responsible for a plethora of physiologic functions, including cognition, mood, movement, and motivation. Not surprisingly, DARs play a role in the etiology and/or therapy of many neuropsychiatric disorders, including schizophrenia and substance use disorder (SUD). There are five DAR subtypes divided into two categories: D1-like (D1R and D5R) and D2-like (D2R, D3R, and D4R). Current antipsychotic medications are antagonists of the D2-like subfamily. However, the lack of selectivity among these D2R-preferring antagonists frequently produce motor-related extrapyramidal side effects, often leading to a lack of compliance among patients. Compounds that selectively antagonize the D3R may lead to fewer side effects while providing effective attenuation of drug craving and/or psychotic symptoms, making the discovery of novel D3R-selective antagonists a priority. A challenge to this goal is posed by the high sequence homology between the D2R and D3R within their orthosteric binding sites. Our lab aims to overcome these selectivity challenges by identifying D3R negative allosteric modulators (NAMs), compounds that inhibit the D3R via binding to an allosteric site. To this end, we screened the NIH Molecular Libraries Program 400,000+ small molecule library and identified MLS6357 as a promising hit compound that exhibited selectivity for the D3R over the D2R in multiple signaling outputs, while displaying an allosteric mechanism of action. Interestingly, radioligand binding assays demonstrated that MLS6357 increases D3R affinity for agonists, indicating that this scaffold is a D3R positive allosteric modulator-antagonist (PAM-antagonist), a special class of NAMs that potentiate agonist-receptor binding while concomitantly decreasing agonist-stimulated receptor signaling. Iterative medicinal chemistry and functional assays were used to synthesize and characterize >100 analogs of MLS6357, with several compounds displaying several-fold increases in potency as antagonists in both β-arrestin recruitment and G-protein activation assays, compared to the parent compound MLS6357. Among them, analogs UNC8747 and UNC6869 also maintained global D3R-selectivity. Additionally, both UNC8747 and UNC6869 appeared to recapitulate the activity of MLS6357 as PAM-antagonists and exhibited brain penetrance at sufficient concentrations to occupy the D3R in vivo , making them promising candidates for in vivo behavioral testing. In addition, several other analogs displayed functional selectivity for inhibiting G-protein activation versus β-arrestin recruitment and vice versa. Site-directed mutagenesis approaches are being utilized to determine the allosteric binding site for this PAM-antagonist scaffold at the D3R. The development of a novel, potent PAM-antagonist with high selectivity for the D3R may provide a therapeutic advance for many neuropsychiatric conditions, including SUD.

Discovery of a First-In-Class Small Molecule Antagonist against the Adrenomedullin-2 Receptor: Structure-Activity Relationships and Optimization

Development of Picomolar Affinity Antagonists and Long‐acting Agonists for the Adrenomedullin and CGRP Receptors Using Combinatorial Peptide Library and Structure‐guided Design Approaches

Cell Active and Functionally-Relevant Small-Molecule Agonists of Calcitonin Receptor.

Targeting the adrenomedullin-2 receptor for the discovery and development of novel anti-cancer agents

Probing the Mechanism of Receptor Activity–Modifying Protein Modulation of GPCR Ligand Selectivity through Rational Design of Potent Adrenomedullin and Calcitonin Gene-Related Peptide Antagonists

Adrenomedullin disulfide bond mimetics uncover structural requirements for AM1 receptor activation

Development of chimeric and bifunctional antagonists for CLR/RAMP receptors

Abstract P2154: A Novel Allosteric Modulator of the Β 1 AR Identified by DNA-encoded Small Molecule Library Screening Demonstrates Unique Pharmacology and Function

Discovery of Novel Dual Adenosine A1/A2A Receptor Antagonists Using Deep Learning, Pharmacophore Modeling and Molecular Docking.

Picomolar affinity antagonist and sustained signaling agonist peptide ligands for the adrenomedullin and calcitonin gene-related peptide receptors

Identification of New Potent A1 Adenosine Receptor Antagonists Using a Multistage Virtual Screening Approach

Rational design of highly stabilized and selective adrenomedullin analogs

Mechanism of Intracellular Allosteric Β2ar Antagonist Revealed by X-ray Crystal Structure

Molecular Basis of Action of a Small-Molecule Positive Allosteric Modulator Agonist at the Type 1 Cholecystokinin Holoreceptor

High throughput screening and structure-activity relationship study of potential α2A-adrenoceptor agonists by LANCETM cAMP assay.

Molecular determinants of antagonist interactions with chemokine receptors CCR2 and CCR5

Structure-based Discovery of Selective Positive Allosteric Modulators of Antagonists for the M2 Muscarinic Acetylcholine Receptor.

Discovery and Mapping of an Intracellular Antagonist Binding Site at the Chemokine Receptor CCR2

Pharmacophore Model-based Design and Synthesis of New Structure Small Molecule CCR2 Inhibitors

Synthesis, Structure–Activity Relationship Studies, and ADMET Properties of 3‐aminocyclohex‐2‐en‐1‐ones As Chemokine Receptor 2 (CXCR2) Antagonists

Discovery, Characterization, and Optimization of a Novel Positive Allosteric Modulator-Antagonist of the D3 Dopamine Receptor